Why did Liz Bar­rett turn her back on a top job at No­var­tis in ex­change for the helm of a biotech you nev­er heard of?

Liz Bar­rett wasn’t look­ing for a job in biotech when she got the call from a cor­po­rate head­hunter she knew well. The tim­ing was ter­ri­ble — just in­to a new job as head of No­var­tis’ glob­al, $14 bil­lion on­col­o­gy group un­der a new CEO look­ing to push a longterm change in cul­ture.

That’s a big deal. And she had moved over from the head role at Pfiz­er on­col­o­gy, an­oth­er Big Phar­ma with a ma­jor mis­sion in on­col­o­gy.

There was al­so one oth­er prob­lem: She didn’t know the com­pa­ny. What was Uro­Gen Phar­ma about? And while she knew of ex­ec­u­tive chair­man Arie Bellde­grun, who led Kite to a $12 bil­lion buy­out, she had nev­er met him be­fore.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER